Is there a subset of patients with metastatic breast cancer in whom you would consider locoregional therapy?

E2108 is a negative trial for LRT for stage IV disease. We need to see the publication to see details. The issue is if this trial had enough power to detect a difference. The trial was designed to detect an improvement in 3 year OS rate from 30% with OST alone to 49.3% for OST+LRT. The final results...

While E2108 should dissuade most of us from pursuing aggressive locoregional therapy for de novo stage IV disease, this study did not specifically address the sub population of patients with oligometastatic disease. I would still consider this approach for patients with a limited # of metastases at ...